Compare Omega Healthcare Investors Inc. Common Stock (OHI) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omega Healthcare Investors Inc. Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Omega Healthcare Investors Inc. Common Stock trades at $45 (market cap $13.66B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: Omega Healthcare Investors Inc. Common Stock is far larger — about 2.7× Oruka Therapeutics Inc. Common Stock's market cap, and Omega Healthcare Investors Inc. Common Stock pays a 6.03% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omega Healthcare Investors Inc. Common Stock for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| OHI | ORKA | |
|---|---|---|
Market Cap | $13.66B | $5.08B |
Volume | 1,351,548 | 685,276 |
Sector | Real Estate | Health |
52-Week High | $51.72 | $113.08 |
52-Week Low | $39.53 | $26.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $17.65B | $4.21B |
Dividend Yield | 6.03% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Omega Healthcare Investors Inc. Common Stock
Omega Healthcare Investors Inc. is a real estate investment trust that owns skilled nursing and assisted living facilities, which it leases to healthcare operators under long-term, primarily triple-net lease structures. It partners with healthcare providers across US and UK markets.
Read more on OHI →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
